SAN FRANCISCO, Oct. 19, 2016 /PRNewswire

Perlara PBC (previously Perlstein Lab PBC) today announced the formation of a drug discovery and development collaboration with Novartis to identify new definitive therapeutics for lysosomal storage disorders, starting with lead program Niemann-Pick Type C Disease. In addition to the collaboration, Novartis has made an equity investment in the company. Financial terms are not disclosed.

“Our expertise in whole-animal phenotypic screens, model organism genetics and automation is complemented by Novartis’ world-class pathway and chemical biology expertise, clinical experience and global leadership,” said Ethan Perlstein, Ph.D., CEO, Perlara PBC. “We are eager to begin this next chapter so that our platform technology and discovery programs can move faster to our goal of helping patients and families impacted by diseases with high unmet need.”

Read More…

News story in C&E News